CATX
Perspective Therapeutics, Inc.
Medical - Devices
Market Cap$267M
5Y Perf.-49.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CATX vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
CATX vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CATX | DBVT |
|---|---|---|
| Industry | Medical - Devices | Biotechnology |
| Market Cap | $267M | $1712.35T |
| Revenue (TTM) | $576K | $0.00 |
| Net Income (TTM) | $-114M | $-168M |
| Gross Margin | -150.2% | — |
| Operating Margin | -184.6% | — |
| Total Debt | $4M | $22M |
| Cash & Equiv. | $62M | $194M |
CATX vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CATX
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Perspective Therape… (CATX) | 100 | 50.1 | -49.9% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CATX vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DBVT leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Perspective Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
CATX
Perspective Therapeutics, Inc.
The Income Pick
CATX is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.58
- Rev growth -100.0%, EPS growth -44.7%
- -66.4% 10Y total return vs DBVT's -87.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Defensive Pick
DBVT carries the broadest edge in this set and is the clearest fit for defensive.
- Beta 1.26, current ratio 3.67x
- 0.3% margin vs CATX's -197.3%
- Beta 1.26 vs CATX's 1.58
Best for: defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CATX | -100.0% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs CATX's -197.3% |
| Stability / Safety | DBVT | Beta 1.26 vs CATX's 1.58 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs CATX's +53.2% |
| Efficiency (ROA) | CATX | -36.6% ROA vs DBVT's -89.0% |
CATX vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCATXLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
CATXPerspective Therapeut…
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CATX5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
CATX1/1
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CATX and DBVT operate at a comparable scale, with $576,000 and $0 in trailing revenue.
| Metric | CATXPerspective Thera… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $576,000 | $0 |
| EBITDAEarnings before interest/tax | -$104M | -$112M |
| Net IncomeAfter-tax profit | -$114M | -$168M |
| Free Cash FlowCash after capex | -$112M | -$151M |
| Gross MarginGross profit ÷ Revenue | -150.2% | — |
| Operating MarginEBIT ÷ Revenue | -184.6% | — |
| Net MarginNet income ÷ Revenue | -197.3% | — |
| FCF MarginFCF ÷ Revenue | -195.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CATX and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CATXPerspective Thera… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $267M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $210M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -2.93x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 20.06x | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.80x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CATX and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CATX leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
CATX delivers a -42.8% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-130 for DBVT. CATX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x.
| Metric | CATXPerspective Thera… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -42.8% | -130.2% |
| ROA (TTM)Return on assets | -36.6% | -89.0% |
| ROICReturn on invested capital | +5.2% | — |
| ROCEReturn on capital employed | +5.2% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.13x |
| Net DebtTotal debt minus cash | -$58M | -$172M |
| Cash & Equiv.Liquid assets | $62M | $194M |
| Total DebtShort + long-term debt | $4M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -948.77x | -189.82x |
CATX leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — CATX and DBVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CATX five years ago would be worth $4,100 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs CATX's +53.2%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs CATX's -18.7% — a key indicator of consistent wealth creation.
| Metric | CATXPerspective Thera… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +29.0% | +4.9% |
| 1-Year ReturnPast 12 months | +53.2% | +110.4% |
| 3-Year ReturnCumulative with dividends | -46.2% | +19.7% |
| 5-Year ReturnCumulative with dividends | -59.0% | -69.1% |
| 10-Year ReturnCumulative with dividends | -66.4% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -18.7% | +6.2% |
Evenly matched — CATX and DBVT each lead in 3 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than CATX's 1.58 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs CATX's 58.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CATXPerspective Thera… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.58x | 1.26x |
| 52-Week HighHighest price in past year | $6.16 | $26.18 |
| 52-Week LowLowest price in past year | $1.96 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +58.4% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 39.3 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
CATX leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates CATX as "Buy" and DBVT as "Buy". Consensus price targets imply 226.4% upside for CATX (target: $12) vs 131.8% for DBVT (target: $46).
| Metric | CATXPerspective Thera… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $11.75 | $46.33 |
| # AnalystsCovering analysts | 11 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
CATX leads this category, winning 1 of 1 comparable metric.
Key Takeaway
DBVT leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). CATX leads in 2 (Profitability & Efficiency, Analyst Outlook). 2 tied.
Best OverallPerspective Therapeutics, I… (CATX)Leads 2 of 6 categories
Loading custom metrics...
CATX vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CATX or DBVT a better buy right now?
Analysts rate Perspective Therapeutics, Inc.
(CATX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CATX or DBVT?
Over the past 5 years, Perspective Therapeutics, Inc.
(CATX) delivered a total return of -59. 0%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: CATX returned -66. 4% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CATX or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Perspective Therapeutics, Inc. 's 1. 58β — meaning CATX is approximately 26% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Perspective Therapeutics, Inc. (CATX) carries a lower debt/equity ratio of 1% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — CATX or DBVT?
On earnings-per-share growth, the picture is similar: Perspective Therapeutics, Inc.
grew EPS -44. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CATX or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -197. 3% for Perspective Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -184. 6% for CATX. At the gross margin level — before operating expenses — DBVT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CATX or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CATX or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Perspective Therapeutics, Inc. (CATX) carries a higher beta of 1. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, CATX: -66. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CATX and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.